Dissecting the dual role of AMPK in cancer: From experimental to human studies

Molecular Cancer Research

Volumn 13, Issue 7, 2015, Pages 1059-1072

  Zadra, Giorgia ^a   Batista, Julie L ^b,c   Loda, Massimo ^a,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PHENFORMIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; META ANALYSIS (TOPIC); METABOLIC REGULATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL PROLIFERATION; METABOLISM; NEOPLASMS; ONCOGENE; PHYSIOLOGICAL STRESS; TUMOR SUPPRESSOR GENE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES; STRESS, PHYSIOLOGICAL;

EID: 84942310743     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0068     Document Type: Review

References (144)

1. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2:28.
2. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13:2004-8.
3. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004; 101:3329-35.
4. Fogarty S, Hardie DG Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010; 1804:581-91.
5. Mihaylova MM, Shaw RJ The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13:1016-23.
6. Liang J, Mills GB AMPK: a contextual oncogene or tumor suppressor? Cancer Res 2013; 73:2929-35.
7. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al Integrative analysis of complex cancer genomicsand clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1.
8. Li J, Jiang P, Robinson M, Lawrence TS, Sun Y. AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 2003; 24:827-34.
9. Fox MM, Phoenix KN, Kopsiaftis SG, Claffey KP AMP-activated protein kinase alpha 2 isoform suppression in primary breast cancer alters AMPK growth control and apoptotic signaling. Genes Cancer 2013; 4:3-14.
10. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, et al AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 2012; 72:4394-404.
11. Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007; 449:496-500.
12. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, et al Structure of mammalian AMPK and its regulation by ADP. Nature 2011; 472:230-3.
13. Hardie DG, Ross FA, Hawley SA AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13:251-62.
14. Steinberg GR, Kemp BE AMPK in health and disease. Physiol Rev 2009; 89:1025-78.
15. Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, et al Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007; 282:32549-60.
16. Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, et al Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic Biol Med 2009; 46:1386-91.
17. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010; 6:457-70.
18. DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep 2014; 9:495-503.
19. Jeon SM, Hay N. The dark face of AMPK as an essential tumor promoter. Cell Logist 2012; 2:197-202.
20. Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, et al Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Mol Cancer Res 2014; 13:620-35.
21. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17:113-24.
22. Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. Cell Cycle 2014; 13:859-68.
23. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005; 65:6719-25.
24. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006; 66:5287-94.
25. Lee JH, Koh H, Kim M, Kim Y, Lee SY, Karess RE, et al Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007; 447:1017-20.
26. Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, et al Chemical genetic screen for AMPKalpha2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 2011; 44:878-92.
27. Thaiparambil JT, Eggers CM, Marcus AI AMPK regulates mitotic spindle orientation through phosphorylation of myosin regulatory light chain. Mol Cell Biol 2012; 32:3203-17.
28. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle 2009; 8:2385-98.
29. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle 2009; 8:3679-83.
30. Merlen G, Gentric G, Celton-Morizur S, Foretz M, Guidotti JE, Fauveau V, et al AMPKalpha1 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expression. J Hepatol 2014; 60: 152-9.
31. Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y, Lee SX, Ou Y, et al Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 2013; 52:161-72.
32. Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, et al AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res 2014; 74:4783-95.
33. Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou YH, et al Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 2015; 160:715-28.
34. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, et al Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 2006; 281:5335-40.
35. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, et al Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33:237-47.
36. Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, et al Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 2013; 123:2907-20.
37. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, et al The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011; 20:315-27.
38. Rodriguez M, Potter DA CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res 2013; 11:780-92.
39. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011; 331:456-61.
40. Hardie DG, Pan DA Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002; 30:1064-70.
41. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011; 25:1041-51.
42. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, et al Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010; 329:1201-5.
43. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661-5.
44. Zhong D, Liu X, Khuri FR, Sun SY, Vertino PM, Zhou W. LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 2008; 68:7270-7.
45. Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG Differential effects of AMPK agonists on cell growth and metabolism. Oncogene 2014 Sep 22. [Epub ahead of print].
46. Laderoute KR, Calaoagan JM, Chao WR, Dinh D, Denko N, Duellman S, et al 5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors. J Biol Chem 2014; 289:22850-64.
47. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, et al AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 2013; 73:2628-38.
48. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Garcia-Caballero T, et al Lipoprotein internalisation induced by oncogenic AMPK activation is essential to maintain glioblastoma cell growth. Eur J Cancer 2014; 50: 3187-97.
49. Hindupur SK, Balaji SA, Saxena M, Pandey S, Sravan GS, Heda N, et al Identificationofanovel AMPK-PEA15 axisinthe anoikis-resistant growth of mammary cells. Breast Cancer Res 2014; 16:420.
50. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, et al Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012; 483:608-12.
51. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348 Pt 3:607-14.
52. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-5.
53. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, et al Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11:390-401.
54. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71:4366-72.
55. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122:253-70.
56. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, et al Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 2014; 111: E435-44.
57. Hardie DG, Alessi DR LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol 2013; 11:36.
58. Faubert B, Vincent EE, Poffenberger MC, Jones RG The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Lett 2015; 356:165-70.
59. Laderoute KR, Calaoagan JM, Madrid PB, Klon AE, Ehrlich PJ SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther 2010; 10:68-76.
60. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412:211-21.
61. Hadad SM, Hardie DG, Appleyard V, Thompson AM Effects ofmetformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014; 16:746-52.
62. Lea MA, Pourat J, Patel R, des Bordes C. Growth inhibition of colon cancer cells by compounds affecting AMPK activity. World J Gastrointest Oncol 2014; 6:244-52.
63. Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt IP, Leung HY AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience 2014; 1:446-56.
64. Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, et al Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem 2011; 286:39247-58.
65. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, et al A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014; 6:519-38.
66. Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget 2014; 5:3785-99.
67. Shen M, Zhang Z, Ratnam M, Dou QP The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. J Cell Physiol 2014; 229:688-95.
68. Valtorta S, Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, et al A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Invest New Drugs 2014; 32:1123-33.
69. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336:918-22.
70. Davies SP, Carling D, Munday MR, Hardie DG Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping. Effects of high fat diets. Eur J Biochem 1992; 203:615-23.
71. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, et al AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8:733-41.
72. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, et al androgens regulate prostate cancer cell growth viaanAMPK-PGC-1alpha-mediated metabolic switch. Oncogene 2014; 33:5251-61.
73. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al Histological evaluation of AMPK signal ling in primary breast cancer. BMC Cancer 2009; 9:307.
74. Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, et al Involvement of metform in and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget 2014; 5:12936-49.
75. Su YW, Lin YH, Pai MH, Lo AC, Lee YC, Fang IC, et al Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck. PLoS One 2014; 9:e96183.
76. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, et al Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 2010; 103:1025-33.
77. Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, et al Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer 2014; 111:25-32.
78. Kang BW, Jeong JY, Chae YS, Lee SJ, Lee YJ, Choi JY, et al Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2012; 70: 735-41.
79. Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ, Oh SY, et al Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncology 2013; 85:78-85.
80. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al Prognostic significance of AMPK activation and therapeutic effects of metformininhepatocellular carcinoma. Clin Cancer Res 2013; 19:5372-80.
81. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, et al. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 2012; 23:78-85.
82. Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, et al A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol 2012; 7:1755-66.
83. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, et al Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010; 5:1894-904.
84. Li C, Liu VW, Chiu PM, Yao KM, Ngan HY, Chan DW Reduced expression of AMPK-beta1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol Cancer 2014; 13:49.
85. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, et al. Gene and protein expression markers of response to combined antian-giogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 2010; 21:1599-606.
86. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-9.
87. Bhandaru M, Martinka M, Li G, Rotte A. Loss of AMPKalpha1 expression is associated with poor survival in melanoma patients. J Invest Dermatol 2014; 134:1763-6.
88. Wangsa D, Heselmeyer-Haddad K, Ried P, Eriksson E, Schaffer AA, Morrison LE, et al Fluorescence in situ hybridization markers for prediction of cervical lymph node metastases. Am J Pathol 2009; 175: 2637-45.
89. Hoffman AE, Demanelis K, Fu A, Zheng T, Zhu Y. Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2013; 22:736-44.
90. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, et al Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 2011; 25:1005-12.
91. Li C, Liu VW, Chiu PM, Chan DW, Ngan HY Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer 2012; 12:357.
92. Vetvik KK, Sonerud T, Lindeberg M, Luders T, Storkson RH, Jonsdottir K, et al Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metabolism 2014; 63:672-81.
93. Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, Kemp BE, Witters LA. Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem J 2001; 354:275-83.
94. Vidal AP, Andrade BM, Vaisman F, Cazarin J, Pinto LF, Breitenbach MM, et al AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. Eur J Endocrinol 2013; 169:521-8.
95. Huang FY, Chiu PM, Tam KF, Kwok YK, Lau ET, Tang MH, et al Semiquantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol 2006; 103:219-25.
96. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, et al Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012; 2:328-43.
97. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, et al Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55:2593-603.
98. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013; 62:922-34.
99. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8:e71583.
100. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35:2665-73.
101. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 2014; 7:867-85.
102. Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, et al Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther 2014; 39:854-63.
103. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al Metformin use and prostate cancer risk. Eur Urol 2014; 66:1012-20.
104. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, et al Metformin does not affect cancer risk: a cohort study in the U. K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014; 37:2522-32.
105. Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L, et al Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 2014; 111:1432-9.
106. Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, et al Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014; 37:1910-7.
107. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31:3069-75.
108. He XX, Tu SM, Lee MH, Yeung SC Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22:2640-5.
109. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, et al The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014; 111:628-36.
110. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL Mortality after incident cancer in people with and without type 2diabetes: impact of metformin on survival. Diabetes Care 2012; 35:299-304.
111. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014; 132:438-42.
112. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132:236-40.
113. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 2013; 112:1105-12.
114. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 2014; 32: 49 e7-14.
115. Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F, et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013; 8:357-63.
116. + breast cancer. Ann Oncol 2012; 23:1771-80.
117. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, et al Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 2013; 16:391-7.
118. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014; 32:43 e1-7.
119. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013; 36:3018-26.
120. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202-11.
121. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 2014; 120:2986-95.
122. Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, et al Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 2015; 4:161-73.
123. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, et al Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 2014; 134: 607-14.
124. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, et al A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 2014; 17:252-8.
125. Kwong SC, Brubacher J. Phenformin and lactic acidosis: a case report and review. J Emerg Med 1998; 16:881-6.
126. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10:143-56.
127. Knapen LM, Dittrich ST, de Vries F, Starup-Linde J, Vestergaard P, Henry RM, et al Use of biguanides and the risk of colorectal cancer: a register-based cohort study. Curr Drug Saf 2013; 8:349-56.
128. Algra AM, Rothwell PM Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13:518-27.
129. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602-12.
130. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379:1591-601.
131. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 2014; 111:623-7.
132. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28: 1467-72.
133. McCowan C, Munro AJ, Donnan PT, Steele RJ Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013; 49:1049-57.
134. Reimers MS, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, van den Broek CB, van de Velde CJ, et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc 2012; 60:2232-6.
135. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596-606.
136. Walker AJ, Grainge MJ, Card TR Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 2012; 107:1602-7.
137. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106:1564-70.
138. Chia WK, Ali R, Toh HC Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012; 9:561-70.
139. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30:3540-4.
140. Flahavan EM, Bennett K, Sharp L, Barron TI A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 2014; 25:154-9.
141. Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG, et al Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control 2014; 25:33-43.
142. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res 2012; 5:1223-8.
143. Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, et al Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. BMC Cancer 2014; 14:391.
144. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, et al Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology 2014; 146:700-8 e2.